Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.

@article{Stasi1997ResponseTR,
  title={Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.},
  author={Roberto Stasi and M. Brunetti and Stefano Bussa and Monia Conforti and Claudio Di Giulio and Alessandra Crescenzi and Edmondo Terzoli and Aldo Vecchione and Amy E Pagano},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 5},
  pages={733-9}
}
Recombinant human erythropoietin (rhEPO) at pharmacological doses was used to improve anemia and reduce the transfusional requirements of 43 patients with myelodysplastic syndrome (MDS). rhEPO was given by s.c. injection three times per week for 12 weeks. The EPO dose was started at 150 IU/kg and was increased to 300 IU/kg if after 6 weeks there was no or suboptimal erythroid response. Responses were defined as being a complete response (CR), partial response (PR), or no response (NR). A CR was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Myelodysplastic syndrome.

Current opinion in hematology • 1995
View 2 Excerpts

Similar Papers

Loading similar papers…